Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Thrombocythemia, Essential 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pheochromocytoma 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hyperaldosteronism 1Endocrine Gland Neoplasms 1Congenital Abnormalities 1Colorectal Neoplasms 1Anemia, Refractory, with Excess of Blasts 1ACTH Syndrome, Ectopic 1

Interventions

Gemcitabine 5Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4selpercatinib 2niraparib 2napabucasin 2entinostat 2Ocoxin 2Irinotecan 2Bevacizumab 2temsirolimus 1tariquidar 1repotrectinib 1pralsetinib 1pembrolizumab 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1ganitumab 1copper dotatate CU-64 1Valproic Acid 1Trabectedin 1Therapeutic Irrigation 1Taxes 1Sunitinib 1Staining and Labeling 1Sirolimus 1Psilocybin 1Phlebotomy 1Paclitaxel 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endocrine Gland Neoplasms × Staining and Labeling × Clear all
NCT05446779 2024-04-16

SuddenDeath

Helsinki University Central Hospital

Active not recruiting
400 enrolled
Endocrine

ACTH Syndrome, Ectopic, Endocrine Gland Neoplasms, Hyperaldosteronism, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡